Drug Trial Radar · NCT06117774
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
404
Actual
Start
Feb 20, 2024
Primary completion
Apr 20, 2030
Study completion Apr 20, 2030
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).
Conditions
- Limited Stage Small Cell Lung Cancer
- Small Cell Lung Cancer
Interventions
TarlatamabDrug
Intravenous (IV) infusion
PlaceboDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS as Determined by BICRTime frame: Up to approximately 6 years
- OS Over the Whole TrialTime frame: Up to approximately 6 years
Locations
204 sites in 27 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California
University of California Los Angeles
Santa Monica, California
Yale New Haven Hospital
New Haven, Connecticut
Boca Raton Clinical Research Global South Florida
Plantation, Florida
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky
Our Lady of the Lake Cancer Institute
Baton Rouge, Louisiana
Morristown Medical Center
Morristown, New Jersey
New York University Grossman School of Medicine and New York University Langone Hospitals
New York, New York
Perlmutter Cancer Center at New York University Langone Hospital - Long Island
New York, New York
Montefiore Einstein Center for Cancer Care
The Bronx, New York
FirstHealth Cancer Center
Pinehurst, North Carolina
Lehigh Valley Health Network
Allentown, Pennsylvania
Spokenword Clinical Trials
Easton, Pennsylvania
Renovatio Clinical
The Woodlands, Texas
US Oncology Research Investigational Products Center
The Woodlands, Texas
University of Virginia Health System
Charlottesville, Virginia
Virginia Cancer Specialists, PC
Fairfax, Virginia
West Virginia University Health Sciences Center
Morgantown, West Virginia
Instituto Argentino de Diagnóstico y Tratamiento
Buenos Aires, Argentina
Fundacion Respirar
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Instituto Oncologico de Cordoba Ionc Fundacion Richardet Longo
Córdoba, Córdoba Province, Argentina
Hospital Aleman Buenos Aires
CABA, Distrito Federal, Argentina
Clinica Viedma
Viedma, Río Negro Province, Argentina
Sanatorio 9 de Julio Cice 9 de Julio
San Miguel de Tucumán, Tucumán Province, Argentina
Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Medizinische Universitaet Graz
Graz, Austria
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, Austria
Institut Jules Bordet
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Instituto Dor de Pesquisa e Ensino
Rio de Janeiro, Brazil
Instituto Cancer Sao Paulo Icesp
São Paulo, Brazil
Hospital Santa Rita
Vitória, Espírito Santo, Brazil
Oncoclinicas Onco Vida Distrito Federal
Brasília, Federal District, Brazil
Liga Paranaense do Combate ao Cancer - Hospital Erasto Gaertner
Curitba, Paraná, Brazil
Showing 40 of 204 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.